Akebia Therapeutics announced a merger agreement with Keryx Biopharmaceuticals to create a company expected to be a leader in the development of renal disease therapies.
Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.
Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.
Nevada-based PDL BioPharma will no longer pursue a proposed acquisition of Neos Therapeutics. PDL made three failed attempts to acquire Texas-based Neos.
Shares of Teva Pharmaceutical were up following news reports that billionaire investor Warren Buffett took a stake in the company.
Gilead Sciences Inc. said fourth-quarter 2017 sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for 2018.
Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.
AstraZeneca saw revenues and product sales fall over the course of 2017. Total revenues declined 2 percent to $22.46 billion and product sales fell 5 percent to $20.15 billion.